AI assistant
Sending…
Niagen Bioscience, Inc. — Director's Dealing 2017
Jul 6, 2017
32418_dirs_2017-07-06_ac96c0cf-5c64-4d4a-9e4f-a1aeeb4b002d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ChromaDex Corp. (CDXC)
CIK: 0001386570
Period of Report: 2017-06-20
Reporting Person: Baxter Jeff (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-06-20 | Stock Options (right to buy) | $3.59 | A | 20000 | Acquired | 2027-06-20 | Common Stock (20000) | Direct |
Footnotes
F1: Options vest 100% on June 20, 2018.
More from Niagen Bioscience, Inc.
Transaction in Own Shares
2026
Jul 10
Declaration of Voting Results & Voting Rights Announcements
2026
Jun 29
Capital/Financing Update
2026
Jun 26
Call Transcript
2026
Jun 11
Call Transcript
2026
May 6
Regulatory Filings
2026
May 6
Capital/Financing Update
2026
Mar 19
Call Transcript
2026
Mar 4
Regulatory Filings
2026
Feb 26
Director's Dealing
2026
Feb 24